Clinical medicine profile
Bromazepam
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Myasthenia gravis
- gradual withdrawal
- hepatic dysfunction
- renal dysfunction
- anxiety with underlying depression disorders [as one of its side effects is depression]
- lactation
- narrow angle glaucoma
- obstet- ric during labour
- diseases of obstruction of airways
- psychosis [as one of its side effects is psychosis].
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
3-18mg daily in divided doses. [Max. 60mg in divided]. Elderly patients given 12 the adults dose.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Short term use in anxiety.
Adverse effects
- Sedation
- depression
- vivid dreams
- psychosis
- suicidal tendency
- hysteria
- constipation diarrhoea
- dry mouth
- withdrawal reactions
- dependence
- paradoxical reactions
- hepatic dysfunction
- blood dyscrasia
- menstrual irregularity
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
Potentiation of effect of Gam- ma-Aminobutyrate [GABA].
Read complete mechanism
Potentiation of effect of Gam- ma-Aminobutyrate [GABA]. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| Drug interactions: See under contraindications | Afya Index product / manufacturer unverified | tabs 5x10's | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.